Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Transcranial Photobiomodulation in Anxiety Disorders

NCT: NCT07133893 · RECRUITING

NCT IDNCT07133893
StatusRECRUITING
Start Date2025-09-01
Completion2028-09

Brief Summary

The investigators have previously shown that safe, non-invasive methods of brain stimulation such as the administration of transcranial infrared light can result in improvements to cognition and emotion. The investigators hypothesize that transcranial photobiomodulation (tPBM) can be used in conjunction with attention bias assessment and modification to reduce anxiety symptoms in individuals with sub-clinical anxiety.

Frequently Asked Questions

What is Transcranial Photobiomodulation in Anxiety Disorders?

Transcranial Photobiomodulation in Anxiety Disorders is a clinical trial registered under NCT07133893. Current status: RECRUITING.

What is the status of NCT07133893?

The current status of NCT07133893 (Transcranial Photobiomodulation in Anxiety Disorders) is: RECRUITING.

When did Transcranial Photobiomodulation in Anxiety Disorders start?

Transcranial Photobiomodulation in Anxiety Disorders started on 2025-09-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.